Abraxane Injectable Suspension (paclitaxel protein-bound particles (albumin-bound)) for injectable suspension
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
Post-Marketing Experience with ABRAXANE and other Paclitaxel Formulations
- Cardiovascular: There have been reports of congestive heart failure, left ventricular dysfunction, and atrioventricular block with ABRAXANE. Most of the individuals were previously exposed to cardiotoxic drugs, such as anthracyclines, or had underlying cardiac history.
Clinical Trial Experience in Metastatic Breast Cancer
- sepsis and neutropenic sepsis